{
  "docId": "019de072-468c-700c-89db-ca818deece7f",
  "docSlug": "40fd19b5105eee76fe8edee20250e12b",
  "documentTitle": "AN2 Therapeutics | IPO Presentation Deck | 27 slides",
  "authorId": "an2-therapeutics",
  "authorName": "AN2 Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 6,
  "pageCount": 27,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide uses a split-layout with a company mission statement on the left and product-specific details on the right.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de072-468c-700c-89db-ca818deece7f/6",
  "deckHref": "/decks/019de072-468c-700c-89db-ca818deece7f",
  "deckJsonHref": "/decks/019de072-468c-700c-89db-ca818deece7f.json",
  "deckAnchorHref": "/decks/019de072-468c-700c-89db-ca818deece7f#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.18,
        "w": 0.68,
        "x": 0.28,
        "y": 0.52
      },
      "kind": "list",
      "text": "Phase 2/3 pivotal trial expected to support U.S. regulatory approval for treatment-refractory MAC lung disease; plan to enroll first patient 1H 2022; topline Phase 2 data mid 2023; Alignment with FDA on Phase 2/3 trial design and IND accepted (December 2021); QIDP, Fast Track, and orphan drug designations granted",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40d45efe-7cf5-4f56-a9cb-ae9c801cc9fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.68,
        "x": 0.28,
        "y": 0.25
      },
      "kind": "list",
      "text": "Ideal Target Product Profile: Novel mechanism of action, broad spectrum antimycobacterial activity; Convenient, once-daily oral dosing; Superior profile compared to SoC combination regimen in preclinical NTM models; Multiple Phase 1 studies out to 28 days of dosing support well-tolerated dose and high probability of target attainment",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a2d2175-9522-4ef1-9e22-01b11f8e4644",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.68,
        "x": 0.28,
        "y": 0.78
      },
      "kind": "list",
      "text": "We expect our boron chemistry expertise to drive future pipeline of differentiated compounds",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c0ddf38a-19fd-4de5-ba90-5bac9dba88ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.68,
        "x": 0.28,
        "y": 0.08
      },
      "kind": "list",
      "text": "Epetraborole (EBO): Pivotal phase 2/3 ready antibiotic product candidate for non-tuberculous mycobacterial (NTM) lung disease",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d42ed221-52e4-4285-bb23-440f38452066",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.68,
        "x": 0.28,
        "y": 0.15
      },
      "kind": "list",
      "text": "Large market opportunity given the high unmet need; Arikayce, the only approved therapy for NTM lung disease, had 2021 WW net sales of >$189M1 in its third year on the market",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f6ffebef-f729-49d7-82fa-cc669bf5884e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.68,
        "x": 0.28,
        "y": 0.72
      },
      "kind": "list",
      "text": "Potential to develop epetraborole to address additional geographies and NTM indications",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff2757ec-dda7-42eb-86e3-9a2b80c17bce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.22,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "AN2 Therapeutics is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8477ded-8781-46dd-a0ee-40eb2de350eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.15,
        "x": 0.28,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Insmed FY 2021 10-K",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e97c659-2c81-41bc-b656-1582d4c7af77",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "e1fa98f9-fd06-413b-9bb9-d3462032fae6",
      "evidence": "The slide contains a list of bullet points describing the Ideal Target Product Profile and other key points.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 27,
      "from": 1,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "5c43fe0e-f0f3-4ff4-8709-c2c99c61b351",
      "evidence": "The deck starts and ends with the company's mission",
      "position": 1,
      "objective": "Present a clear mission and vision for AN2 Therapeutics",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}